Cost-Offsets of New Medications for Treatment of Schizophrenia
NBER Working Paper No. 12643
Broad claims are frequently made that new medications will offset all or part of their costs by reducing other areas of Medicaid spending. In this paper we examine the net impact on spending for new drugs used to treat schizophrenia. We extend research in this area by taking a new approach to identification of spending impacts of new drugs. We specify and estimate models of spending on treatment of schizophrenia using 7 years of Florida Medicaid data. The estimates indicate that use of the new drugs result in net spending increases. This may be due to increased adherence to treatment.
Document Object Identifier (DOI): 10.3386/w12643
Users who downloaded this paper also downloaded these: